Suppr超能文献

无症状高危糖尿病患者无症状性冠状动脉疾病的预测因子及其预后影响。

Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus.

机构信息

Department of Cardiology, University Hospital, University of Basel, Switzerland.

Department of Cardiology, University Hospital, University of Basel, Switzerland.

出版信息

Int J Cardiol. 2017 Oct 1;244:37-42. doi: 10.1016/j.ijcard.2017.05.069.

Abstract

AIMS

Evaluation of predictors of silent coronary artery disease (SCAD) in high-risk asymptomatic diabetic patients and to evaluate their two-year outcome.

METHODS AND RESULTS

Four hundred diabetic patients without prior CAD but at high CAD risk underwent myocardial perfusion scintigraphy (MPS) in this prospective multicentre outcome trial. MPS were abnormal in 22% of patients. Male sex (OR 2.223, 1.152-4.290; p=0.017), diabetes duration (OR 1.049,1.015-1.085; p=0·005), peripheral artery disease (OR 2.134, 1·150-3.961; p=0.016), smoking (OR 2.064, 1.109-3.839; p=0·022), systolic blood pressure (OR 1.014, 1.00-1.03, p=0·056), brain natriuretic peptide (OR 1.002, 1.001-1.004, p=0·005) independently predicted an abnormal MPS: if <2 and >3 predictors were present, 3.2% and 47% patients had an abnormal MPS, respectively (p<0·001). Two-year major adverse cardiac event rates increased from 2·9% to 14·6%, cardiac death rates from 0·6% to 4·1% in patients with summed stress scores ≤10 and >10%, respectively (each p<0.045).

CONCLUSIONS

Male sex, diabetes duration, peripheral artery disease, smoking, elevated systolic blood pressure and increased brain-natriuretic peptides independently predicted SCAD. In presence of >3 predictors, almost 50% of patients had an abnormal MPS. They may benefit from screening by MPS since the extent of the MPS abnormality discriminated clearly between a favourable compared to a bad 2-year outcome. However, even highest risk patients without objective evidence of CAD had a benign prognosis without need for specific evaluation or therapy.

TRIAL REGISTRATION NUMBER

ISRCTN87953632.

摘要

目的

评估高危无症状糖尿病患者无症状性冠状动脉疾病(SCAD)的预测因素,并评估其两年的结果。

方法和结果

在这项前瞻性多中心结局试验中,400 名无先前 CAD 但 CAD 风险高的糖尿病患者接受了心肌灌注闪烁显像(MPS)。22%的患者 MPS 异常。男性(OR 2.223,1.152-4.290;p=0.017)、糖尿病病程(OR 1.049,1.015-1.085;p=0·005)、外周动脉疾病(OR 2.134,1·150-3.961;p=0·016)、吸烟(OR 2.064,1.109-3.839;p=0.022)、收缩压(OR 1.014,1.00-1.03,p=0.056)、脑钠肽(OR 1.002,1.001-1.004,p=0.005)独立预测 MPS 异常:如果 <2 和 >3 个预测因素存在,分别有 3.2%和 47%的患者 MPS 异常(p<0·001)。两年主要不良心脏事件发生率从 2.9%增加至 14.6%,心脏死亡率从 0.6%增加至 4.1%,分别在总和应激评分≤10 和 >10%的患者中(p<0.045)。

结论

男性、糖尿病病程、外周动脉疾病、吸烟、升高的收缩压和脑钠肽升高独立预测 SCAD。如果存在 >3 个预测因素,近 50%的患者 MPS 异常。他们可能受益于 MPS 筛查,因为 MPS 异常的程度清楚地区分了有利的 2 年预后和不良的预后。然而,即使是没有 CAD 客观证据的高危患者也有良性预后,无需进行特定的评估或治疗。

临床试验注册号

ISRCTN87953632。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验